ABT-737

Catalog No.S1002

ABT-737 Chemical Structure

Molecular Weight(MW): 813.43

ABT-737 is a BH3 mimetic inhibitor of Bcl-xL, Bcl-2 and Bcl-w with EC50 of 78.7 nM, 30.3 nM and 197.8 nM in cell-free assays, respectively; no inhibition observed against Mcl-1, Bcl-B or Bfl-1. Phase 2.

Size Price Stock Quantity  
In DMSO USD 384 In stock
USD 120 In stock
USD 200 In stock
USD 570 In stock
USD 970 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 91 Publications

17 Customer Reviews

  • Cardiomyocytes transduced with or without Ad-Mst1 were treated with ABT-737 (0, 0.1, 1, 10 uM) for 12 hours. Representative immunoblots with antibodies to p62/SQSTM1, LC3 and GAPDH are shown.

    Nat Med 2013 19(11), 1478-88. ABT-737 purchased from Selleck.

    BCL-XL mediates human neutrophil survival. PMNs were preincubated with the BH3 mimetic ABT-737 (1–10 μM), then cultured in normoxia (gray bars) with or without GM-CSF (500 U/ml) or hypoxia (white bars)or 20 hours, and apoptosis was assessed by morphology (n = 4).

     

     

    J Clin Invest 2011 121, 1053-1063. ABT-737 purchased from Selleck.

  • Release of mitochondrial cytochrome c and loss of mitochondrial membrane potential after exposure to ABT-737 (100nM) for 2 hours were assessed by immunohistochemistry and staining with TMRE (red, top panels) and anti-CD41/FITC (green, top panels). Bar represents 5 um. Note that control cells display spreading on glass slides, whereas ABT-737-treated cells do not.

    Blood 2011 17(26), 7145-54. ABT-737 purchased from Selleck.

    Platelets were incubated in HBS with or without ABT-737 (100nM) for 2 hours before analysis by immunohistochemistry and confocal microscopy. Actin was stained using phalloidin/Alexa-488 (green), and tubulin was stained using anti-tubulin/phycoerythrin (red). Bar represents 5 uM.

    Blood 2011 17(26), 7145-54. ABT-737 purchased from Selleck.

  • (B) The sensitivity (LD50) of CLL cells, assessed by annexin V staining after 48 h of treatment with ABT‐737, ABT‐263 or ABT‐199, was plotted against the pBcl‐2/Bcl‐2, Mcl‐1/Bcl‐2 and (pBcl‐2 + Mcl‐1)/Bcl‐2 ratios. Relative protein quantification was carried out with kodak carestream molecular imaging software and normalized to β‐actin. Spearman's correlation (r) and P values are shown. Data shown are representative of five independent experiments.

    Br J Pharmacol, 2016, 173(3):471-83. ABT-737 purchased from Selleck.

    Analysis of SW480 and SW620 cell sensitivity to the BH3-mimetic ABT-737. (a, b) Percentage of apoptosis in adherent or suspended SW480 (a) or SW620 (b) cells cultured in the presence (ABT-737) or absence (ctrl) of ABT-737 (1 uM).

    Cell death dis 2013 4, e801. ABT-737 purchased from Selleck.

  • Bcl-XL/Bcl-2 inhibitor ABT-737 aggravates the proapoptotic effects of IL-1IFN-. INS-1E cells were transfected with single or smart Pool PUMA siRNAs and exposed to ABT-737 for 24 h. At this time point, cell death was measured by HO/PI, n  3. *, p  0.05; **, p  0.01.
     

     

     

    J Biol Chem 2010 285, 19919-19920. ABT-737 purchased from Selleck.

    Effect of ABT-737 on the cell viability of CCRF-CEM cells by treatments of AY4 (10 μg/ml), TRAIL (0.5 μg/ml), SAHA (1 μM),VPA (1 mM), or ABT-737 (10 μM) alone or in combination for 24 h prior to MTT assay.

     

     

    Apoptosis 2010 15, 1256-1269. ABT-737 purchased from Selleck.

  • Effects of ABT-737 and RES, applied alone and in combination, on the viability of MOLT-4 cells.

    Toxicol In Vitro, 2017, 42:38-46. ABT-737 purchased from Selleck.

    Upper panel ABT-737 inhibits TFK-1 and EGI-1 cell growth.Cells were exposed to ABT-737 at a concentration ranging from 1 to 50 lM. Following 72 h of incubation, growth inhibition was analyzed by crystal violet assay. Dose–effect plot of ABT-737 treatment is presented.

     

     

    Cancer Chemoth Pharm 2011 67, 557-567. ABT-737 purchased from Selleck.

  • Lower panel detection of PARP-1, cleaved caspase-9 and caspase-3, BCL-2 and MCL-1 in TFK-1 and EGI-1 cells after 72 h of ABT-737 treatment (1, 3, 10, 25,50 μM). Cell lysates were analyzed on Western blotting.

     

     

    Cancer Chemoth Pharm 2011 67, 557-567. ABT-737 purchased from Selleck.

    3 μM ABT737 inhibited growth and viability of TF-1 cells and potentiated proapoptotic effects of 1 μM BIO after 72 hours treatment. TF-1 cells treated with both drugs exhibited more apoptotic cells compared to those treated with each single drug. ABT737 abrogated the protection from BIO-induced apoptosis provided by MS5 coculture.

     

     

    Exp Hematol 2010 38, 908-921. ABT-737 purchased from Selleck.

  • GSIXII synergized with ABT-737 to trigger apoptosis in breast cancer cells . Breast cancer cell lines were incubate d for 48 hours with 10μM GSIXII or DMSO (Ct) in combination or not with ABT-737, 1 μM. Then apoptosis was evaluated with Apo2.7 or Annexin-V staining and flow-cytometry analysis. Represented data are the means of positive cells ± SEM, from three independent experiments.(A) Suboptimal concentrations of GSIXII (5 μM) and 1 μM ABT-737 were used alone or in combination in MFU assay in MCF7 and BT549 cell lines. Results were obtained from three independent experiments and compared with mock-treated condition. (B) The 20 μM SAHM1 was used alone or in combination in MFU assay in MCF7 and BT549 cell lines. Results were obtained from three independent experiments and compared with the mock-treated condition.

    Biochem Biophys Res Commun 2013 408, 344-9. ABT-737 purchased from Selleck.

    Apoptosis induced by BCL2-inhibitors in P-glycoprotein expressing cells. MDCKII wild type or MDR1 cells were exposed to different concentrations of ABT-737 (C) or ABT-263 (D) for 24 h before apoptosis was assessed by flow cytometry using externalization of phosphatidylserine.

    Biochem Biophys Res Commun 2012 408, 344-9. ABT-737 purchased from Selleck.

  • The combined use of ABT-737 and sorafenib changes the apoptotic effect. MC-3 cells were treated with the indicated compounds for 48 h. (A) Nuclear condensation and fragmentation were evaluated in DAPI-stained cells as described in the Materials and Methods (X400). (B) Live (green) and dead (red) cells were qualified using the Live/dead assay kit as described in the Materials and Methods (X200). (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)

    Arch Oral Biol, 2017, 73:1-6. ABT-737 purchased from Selleck.

    MEF wt and MEF Mcl-1 ko mice activating active caspase-3 using 1um ABT for 24h

     

     

    Dr. Arnim Weber of Medizinische Mikrobiologie und Hygiene Universitatsklinikum Freiburg. ABT-737 purchased from Selleck.

  • MDB-MA-231 cells were exposed to 30 um cisplatin in the absence or in thepresence of 100nm ABT-737.The cell were stained with Hoechst 33342,MitoTracker Red and Yo-pro-1.

     

     

    Dr. Zhang of Tianjin Medical University. ABT-737 purchased from Selleck.

Purity & Quality Control

Choose Selective Bcl-2 Inhibitors

Biological Activity

Description ABT-737 is a BH3 mimetic inhibitor of Bcl-xL, Bcl-2 and Bcl-w with EC50 of 78.7 nM, 30.3 nM and 197.8 nM in cell-free assays, respectively; no inhibition observed against Mcl-1, Bcl-B or Bfl-1. Phase 2.
Features First-generation inhibitor of anti-apoptotic Bcl-2 proteins.
Targets
Bcl-2 [1]
(Cell-free assay)
Bcl-xL [1]
(Cell-free assay)
Bcl-w [1]
(Cell-free assay)
Bcl-B [1]
(Cell-free assay)
30.3 nM(EC50) 78.7 nM(EC50) 197.8 nM(EC50) 1.82 μM(EC50)
In vitro

ABT-737 shows low activity to Bcl-B and no effects to Mcl-1 and BFL-1. ABT-737 is sensitive to HL60, KG1 and NB4 cells with IC50 of 50 nM, 80 nM and 80 nM, respectively. ABT-737 induces apoptosis in HL60 cells, which due to decreased Bcl-2/Bax heterodimerization and has no effect on cell cycle distribution. ABT-737 also induces cytochrome c release from purified mitochondria and promotes conformational changes in Bax that are associated with apoptosis. [1] Resistant cells (Hela and MCF-7) can be sensitized to ABT-737 by approaches that down-regulate, destabilize, or inactivate Mcl-1. ABT-737 also causes Bax/BAK-dependent cytochrome c release only when Mcl-1 has been neutralized. [2] ABT-737 displaces Bim from Bcl2's BH3-binding pocket, allowing Bim to activate Bax, induce mitochondrial permeabilization, and rapidly commit the primary chronic lymphocytic leukemia (CLL) cells to death. [3] Knockdown of Mcl-1 with siRNA sensitizes two resistant SCLC cell lines H196 and DMS114 to ABT-737 by enhancing the induction of apoptosis. Likewise, up-regulation of Noxa sensitizes H196 cells to ABT-737. ABT-737 inhibits proliferation and induces apoptosis in many SCLC cell lines including NCI-H889, NCI-H1963, NCI-H1417, NCI-H146 and etc. Bcl-2 and Noxa may contribute mechanistically to the cellular response to ABT-737 in NCI-H146 cells. [4] A recent study shows that ABT-737 significantly induces apoptosis in HTLV-1 infected T-cell lines as well as in fresh ATLL cells. [5]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
OCI-Ly1  MVXD[YxtKF[rYXLpcIl1gSCDc4PhfS=> M{DUc|I2OCCwTdMg NGrlS5c4OiCq M4nOSWROW09? M1TJR4NifXOnZDC5O{UhdG:|czDv[kB3cWGkaXzpeJkhcW5iY3XscJMhfHKjboPm[YN1\WRid3n0bEBDS0x4IIPpVm5C M2fEWlI3PjV5Mki4
KG1a Mm[1R4VtdCCYaXHibYxqfHliQYPzZZk> NYHKeFRtOC1zMDFOwG0> NEfMO3gzPCCq Mnn2SG1UVw>? MV7JR|UxRTdwNkig{txONCCmZXPy[YF{\XNiY3XscEB3cWGkaXzpeJkhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> MlWxNlY2PTJ5MUK=
Kasumi-1 MYLD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NGfXV4kxNTFyIN88US=> MorrNlQhcA>? NU\vUmtsTE2VTx?= MnHFTWM2OD12Lki3JO69VSxiZHXjdoVie2W|IHPlcIwhfmmjYnnsbZR6KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz M1ziSlI3PTV{N{Gy
KG1a M1WwNmFxd3C2b4Ppd{BCe3OjeR?= Mn;VNE0yOCEQvF2= NIflfo8zPCCq MnvsSG1UVw>? NXzuT4czcW6mdXPld{Bk\WyuIHHwc5B1d3OrczDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= MWCyOlU2OjdzMh?=
Kasumi-1 MVPBdI9xfG:|aYOgRZN{[Xl? M2\MeVAuOTBizszN NV3GUYJnOjRiaB?= NHO3boJFVVOR NIXPeZRqdmS3Y3XzJINmdGxiYYDvdJRwe2m|IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ NInoWHkzPjV3MkexNi=>
MC-3  NU\aRY5JT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYXz[4JTPS9zMD:yNEDPxE1? MYiyOEBp NEXydZZFVVOR NV3W[nBbcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? Ml:2NlY1PDd4MUW=
HN22  NEfmbpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYTxOIs2Oi53L{euOU8zOi53IN88US=> MXGyOEBp NIiydnlFVVOR MYTpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> MoO0NlY1PDd4MUW=
MC-3  M4X5fGFxd3C2b4Ppd{BCe3OjeR?= NHv1bJc2NzFyL{KwJO69VQ>? NHqy[pIzPCCq NYC2cG1KTE2VTx?= NXPZZZZScW6mdXPld{Bk[XOyYYPlMY1m\GmjdHXkJIFxd3C2b4Ppdy=> MY[yOlQ1PzZzNR?=
HN22  NU\Eb5pQSXCxcITvd4l{KEG|c3H5 MlHsNk42NzdwNT:yNk42KM7:TR?= NFXQPI8zPCCq MYjEUXNQ MWPpcoR2[2W|IHPhd5Bie2VvbXXkbYF1\WRiYYDvdJRwe2m| MoTONlY1PDd4MUW=
MOLT-4 Mn3IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH3PdHQyOC13MECwJI5O NVT2SXpHPzJiaB?= NGLR[JFFVVOR NF\lW5dKSzVyPUCuNVk5KM7:TR?= MkGyNlY{QTJ|M{K=
RS4;11 NX7IOWZMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVjJUXd6OTBvNUCwNEBvVQ>? NHXOblY4OiCq MVvEUXNQ MYDJR|UxRTBwMECyJO69VQ>? NX7XeJRbOjZ|OUKzN|I>
JURKAT MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlTnNVAuPTByMDDuUS=> NWrwSmJDPzJiaB?= M122PWROW09? MnXnTWM2OD14NjFOwG0> MWqyOlM6OjN|Mh?=
CEM R MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnjDNVAuPTByMDDuUS=> M1XDVlczKGh? MoPvSG1UVw>? NXrJZpVxUUN3ME21MlQh|ryP MknpNlY{QTJ|M{K=
CEM S NY\1UYZoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3XpSlExNTVyMECgcm0> MonPO|IhcA>? MWHEUXNQ MnzxTWM2OD1zMj6xJO69VQ>? MYKyOlM6OjN|Mh?=
MOLT-4 NYTOTXRkSXCxcITvd4l{KEG|c3H5 MYGxNE0yODByIH7N MoD4NlQhcA>? MVPEUXNQ NEHyU5Jk[XW|ZYOgeIhmKGOuZXH2ZYdmKG:oIFLjcE0zKGGwZDD0bIUh\G:5boLl[5Vt[XSrb36gc4YhSmOuLYjMJIFv\CCPY3ytNS=> NF\4W5YzPjN7MkOzNi=>
CEM S MnLRRZBweHSxc3nzJGF{e2G7 M{DxdlExNTFyMECgcm0> NIm0U3gzPCCq NUXIZ40xTE2VTx?= NIPjVFFk[XW|ZYOgeIhmKGOuZXH2ZYdmKG:oIFLjcE0zKGGwZDD0bIUh\G:5boLl[5Vt[XSrb36gc4YhSmOuLYjMJIFv\CCPY3ytNS=> MnTyNlY{QTJ|M{K=
JURKAT MmHoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXX2UnJwOTByLUGwNFAhdk1? NIXieHc1QCCq M2OzWGROW09? Mn75TWM2OD17NUZCtVkvOyCwTR?= NGTKO2gzPjF5MkK2PS=>
LOUCY NXTQcI1WT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV6xNFAuOTByMDDuUS=> Mne3OFghcA>? MUPEUXNQ Mk\GTWM2OD1|Mj64xtEyOC57IH7N MVWyOlE4OjJ4OR?=
WM-115 M3LqU2NmdGxiVnnhZoltcXS7IFHzd4F6 NGDuXFMyODEEoH7N MXG3NkBp NGnKc|BmdmijbnPld{BkfXKldX3pck1qdmS3Y3XkJIFvfGlvc4Xyeol3[W{EoB?= NHf0flIzPjFzNke3Oi=>
B16 NV;6UZFnS2WubDDWbYFjcWyrdImgRZN{[Xl? NYnEOlR{OTBywrDuUS=> NEG2N2c4OiCq MXLlcohidmOnczDjeZJkfW2rbj3pcoR2[2WmIHHueIkue3W{dnn2ZYzDqA>? MYOyOlEyPjd5Nh?=
HL-60  MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoTlO|IhcA>? M3jK[GlEPTEEoE2gNVAvPyCwTR?= NH7oWXEzPjB2NU[wPS=>
MOLM-13  MlzIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX63SlNnPzJiaB?= NYjNNZdwUUN3MNMgQUAzPy57IH7N MVGyOlA1PTZyOR?=
OCI-AML3 M3TDS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnLnO|IhcA>? MYLJR|UxyqB;IEG5OVAhdk1? NFXFVFIzPjB2NU[wPS=>
BCWM.1 MlTVRZBweHSxc3nzJGF{e2G7 NX7KblJ7OC1zLk[g{txO NHLnNHEzPCCq NHfpUFdqdmS3Y3XzJINmdGxiYYDvdJRwe2m| MnzrNlU5QTN{OUC=
MWCL-1 M4DBcGFxd3C2b4Ppd{BCe3OjeR?= MljWNE0yNjZizszN MWOyOEBp M2P3UIlv\HWlZYOgZ4VtdCCjcH;weI9{cXN? M3r2VVI2QDl|Mkmw
MM.1s MmLNRZBweHSxc3nzJGF{e2G7 M1L2Z|AuOS54IN88US=> MWOyOEBp NHTUSlBqdmS3Y3XzJINmdGxiYYDvdJRwe2m| NEP1WpIzPTh7M{K5NC=>
HCT116 MXTGeY5kfGmxbjDBd5NigQ>? M17FN|MwOTBizszN M1iye|EzyqCqwrC= NWDNZ|hFTE2VTx?= M4K3eolv\HWlZYOgZUBld3OnLXTldIVv\GWwdDDpcoNz\WG|ZTDpckBNSzOELVnJJINwdn[ncoPpc44h[W6mIGPRV3ROOSCmZXfyZYRifGmxbh?= MoOxNlU4OTVyMki=
HCT116 BAX BAK1 DKO Ml22SpVv[3Srb36gRZN{[Xl? M{LzfFMwOTBizszN M1vXXFEzyqCqwrC= NUX1b2tqTE2VTx?= Mn:5bY5lfWOnczDhJIRwe2VvZHXw[Y5l\W62IHnuZ5Jm[XOnIHnuJGxEO0JvSVmgZ49vfmW{c3nvckBidmRiU2HTWG0yKGSnZ4Lh[IF1cW:w M1jUelI2PzF3MEK4
HCT116 NIH4XItHfW6ldHnvckBCe3OjeR?= MY[xNEDPxE1? MU[xNuKhcMLi NYP4d3UzTE2VTx?= M4TLWIlv[3KnYYPld{BITlBvTFOzRkBxfW6ldHG= MVmyOVcyPTB{OB?=
HCT116 BAX BAK1 DKO MVvGeY5kfGmxbjDBd5NigQ>? MVSxNEDPxE1? MkjiNVLDqGkEoB?= NIniPJRFVVOR M1GwNolv[3KnYYPld{BITlBvTFOzRkBxfW6ldHG= MUiyOVcyPTB{OB?=
HCT116 NXHsTlkxSXW2b4DoZYd6KEG|c3H5 MYWxNEDPxE1? Mle2NVLDqGkEoB?= MknhSG1UVw>? MXPpcoR2[2W|IHGgZ49ueGyndHWgZZV1d3CqYXfpZ{Bz\XOyb37z[S=> NGfndG8zPTdzNUCyPC=>
HCT116 BAX BAK1 DKO M1;5cWF2fG:yaHHnfUBCe3OjeR?= NF7wTmUyOCEQvF2= NGS5ZZYyOsLiaNMg NEDmfFRFVVOR NYPnd3V3cW6mdXPld{BiKGOxbYDs[ZRmKGG3dH;wbIFocWNicnXzdI9ve2V? Ml3CNlU4OTVyMki=
U937 NXmyR|BjSXCxcITvd4l{KEG|c3H5 MlXRNE4yOjVvMjFOwG0> MnXmNlQhcA>? NUnwTVNF\W6qYX7j[ZMhTEiDL2itNVEucW6mdXPl[EBieG:ydH;zbZM> M4HZelI2PzF2MEK0
U937  M2Ow[mFxd3C2b4Ppd{BCe3OjeR?= Mo\ONE42KM7:TR?= NWexc2QyOjRiaB?= MmLa[Y5p[W6lZYOgZ4xm[X[jZ3Wgc4YhWEGUUDDhcoQh[2G|cHHz[U0{KGG|IIflcIwh[XNiTn;4ZUBt\X[nbB?= MWSyOVcyPDB{NB?=
HL-60 AAA-Bcl-2 MmTYRZBweHSxc3nzJGF{e2G7 NYDzdXhxOC13IN88US=> NVX6SHNEPDhiaB?= MlzxTWM2OD1yLki3JO69de,:jHnu[JVk\XNiY3XscEBieG:ydH;zbZMhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> M4G2SFI2PzFzNE[w
HL-60 EEE-Bcl-2 MkjpRZBweHSxc3nzJGF{e2G7 NF;ObHExNTVizszN NVe2XIRzPDhiaB?= NXrTS4xrUUN3ME21JO69de,:jDDpcoR2[2W|IHPlcIwh[XCxcITvd4l{KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz NUL4[mVjOjV5MUG0OlA>
U87 MXXGeY5kfGmxbjDBd5NigQ>? M3rlelUxKM7:TR?= NYLyUlFGOjRiaB?= MYry[YR2[2W|IITo[UBuWk6DIHX4dJJme3Orb36gcIV3\Wy|IH;mJG1OWC1{LDDNUXAuOTRiYX7kJGJkdC1{ M4TkWFI2PjZ5Nk[z
K562 MnPhR4VtdCCYaXHibYxqfHliQYPzZZk> MkTHNU0yOCEQvF2= MkDnOFghcA>? NX3VSFV3TE2VTx?= MmPMTWM2OD1{Nj63JO69VQ>? NYLIOJBYOjV3OU[1OlE>
K562/Mcl -1-IRESBim MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX3JR|UxRTlwMzFOwG0> MmfNNlU2OzV7MEC=
K562/Bcl- 2-IRESBim NGXybYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWe5e2VuUUN3ME2wMlM2KM7:TR?= MnXVNlU2OzV7MEC=
Jurkat M3;kVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIPheppKSzVyPUCuOlYh|ryP NInLdZUzPTV|NUmwNC=>
JurkatΔBak NHXtT4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXvJR|UxRjVyIN88US=> NGDkeJMzPTV|NUmwNC=>
HL60/VCR M2rSU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEiwNmpKSzVyPkGwNEDPxE1? NEn1R|YzPTV|NUmwNC=>
Kasumi-1 NEXYV|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NG\P[mZKSzVyPUCuNFEh|ryP NXS4WlB6OjV3M{W5NFA>
Kasumi-1/ABT NWCybXAyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH3NbmdKSzVyPUCuOVEh|ryP NGrKe2szPTV|NUmwNC=>
THP-1 MnP3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlPFTWM2OD1zLkK3JO69VQ>? NH34NoszPTV|NUmwNC=>
U937 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWPJR|UxRTVwMkmg{txO NUHtRZc6OjV3M{W5NFA>
C1498 M3vMPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXTJR|UxRTZwMUOg{txO MUOyOVU{PTlyMB?=
RPMI 8226 Mn7TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmXnTWM2OD1yLkK1JO69VQ>? Mle2NlU2OzV7MEC=
MM.1S NF;5NXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVXL[25IUUN3ME2wMlQxKM7:TR?= M1H1PVI2PTN3OUCw
NCI-H929 NWrvUVNnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWO5eYFVUUN3ME2xOU4zOSEQvF2= M1WxVlI2PTN3OUCw
U266 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUK2fpBIUUN3ME2wMlY5KM7:TR?= MnToNlU2OzV7MEC=
MCF-7 M2DYdGNmdGxiVnnhZoltcXS7IFHzd4F6 MVi1JO69VQ>? NFrTWXQ1QCCq NGjpfGlFVVOR NF\zU5ZmdmijbnPld{B1cGVic3Xud4l1cX[rdImgeI8hd3JicnHkbYF1cW:w NYLHbWZIOjV2MEmxNlQ>
MCF-7 M4DVeWFxd3C2b4Ppd{BCe3OjeR?= MnzNOUDPxE1? MmPlOE8zPC92ODDo NVn1b2RITE2VTx?= MXHpcoNz\WG|ZYOgeIhmKGOuZXH2[YQhWEGUUB?= MVqyOVQxQTF{NB?=
MCF-7 NXHHSFMxTnWwY4Tpc44hSXO|YYm= M3f4V|Uh|ryP NIHmWGgzPCCq MljWSG1UVw>? M{PPNYVvcGGwY3XzJJRp\WyndnXsJI9nKE2lbD2xJIV5eHKnc4Ppc47DqA>? NH;Y[pgzPTRyOUGyOC=>
MDA-MB 231  NYjweVN5TnWwY4Tpc44hSXO|YYm= MlTlOUDPxE1? MmjPNlQhcA>? MWDEUXNQ MWTlcohidmOnczD0bIVt\X[nbDDv[kBO[2xvMTDlfJBz\XO|aX;uxsA> MXeyOVQxQTF{NB?=
ZR-75-1  NFO5fYdHfW6ldHnvckBCe3OjeR?= NUe1VHExPSEQvF2= M4LsZVI1KGh? NYXwcWtzTE2VTx?= NFHxU3hmdmijbnPld{B1cGWuZY\lcEBw\iCPY3ytNUBmgHC{ZYPzbY9vyqB? NGTRSXgzPTRyOUGyOC=>
A549 MVvD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NWHJXW0xOC1{MDFOwG0> MUe3NkBp NUDvdWllTE2VTx?= MYTk[YNz\WG|ZYOgeIhmKGOnbHygd5Vzfmm4YXygbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYKgZ49u[mmwZXSge4l1cCCjc4Dpdolv MkXuNlU{QDh5NkK=
H1299 NWXnWZFbS2WubDDWbYFjcWyrdImgRZN{[Xl? NH3VcG4xNTJyIN88US=> NWPjPY45PzJiaB?= MlvhSG1UVw>? MVLk[YNz\WG|ZYOgeIhmKGOnbHygd5Vzfmm4YXygbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYKgZ49u[mmwZXSge4l1cCCjc4Dpdolv MUSyOVM5QDd4Mh?=
HO-8910 NWjjUpU{S2WubDDWbYFjcWyrdImgRZN{[Xl? MYCwMVIxKM7:TR?= M32zS|czKGh? NWHsNIRwTE2VTx?= M1PIUIRm[3KnYYPld{B1cGViY3XscEB{fXK4aY\hcEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldkBkd22kaX7l[EB4cXSqIHHzdIlzcW5? NFzqfG4zPTN6OEe2Ni=>
HT-29 NVvoU5d3S2WubDDWbYFjcWyrdImgRZN{[Xl? MUOwMVIxKM7:TR?= Ml\nO|IhcA>? Mn;LSG1UVw>? NWTOW4RV\GWlcnXhd4V{KHSqZTDj[YxtKHO3co\peoFtKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVzKGOxbXLpcoVlKHerdHigZZNxcXKrbh?= MXyyOVM5QDd4Mh?=
HCT-116 M3rab2NmdGxiVnnhZoltcXS7IFHzd4F6 MXqwMVIxKM7:TR?= Mn;FO|IhcA>? M2HoUGROW09? NEWwXXNl\WO{ZXHz[ZMhfGinIHPlcIwhe3W{dnn2ZYwhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZIh[2:vYnnu[YQhf2m2aDDhd5Bqemmw MYWyOVM5QDd4Mh?=
A549 NH;0VXlCeG:ydH;zbZMhSXO|YYm= MWGyNEDPxE1? MlXIOFghcA>? NWnmNpNrTE2VTx?= MYrpcoR2[2W|IHHwc5B1d3OrczDzbYdvcW[rY3HueIx6KGOxbXLpcoVlKHerdHigZZNxcXKrbh?= M3jvdVI2Ozh6N{[y
H1299 MoHYRZBweHSxc3nzJGF{e2G7 MVGyNEDPxE1? M2CxOVQ5KGh? NFHoPHRFVVOR MmHpbY5lfWOnczDhdI9xfG:|aYOgd4lodmmoaXPhcpRtgSClb33ibY5m\CC5aYToJIF{eGm{aX6= MnTGNlU{QDh5NkK=
Sc-1 MX\D[YxtKF[rYXLpcIl1gSCDc4PhfS=> NF7kU4gxNjByMEGtNUDPxE1? NYnB[IoyQTZiaB?= MYDk[YNz\WG|ZYOgeIhmKGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy M3LkZVI2Ozd|NUC4
OcI-LY18 NWDWe|F4S2WubDDWbYFjcWyrdImgRZN{[Xl? NIS1Z|YxNjByMEGtNUDPxE1? NGrU[4M6PiCq M4HwNIRm[3KnYYPld{B1cGViY3XscEB3cWGkaXzpeJkhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> M3rtZlI2Ozd|NUC4
RL  NV;WSGpZS2WubDDWbYFjcWyrdImgRZN{[Xl? MYKwMlAxODFvMTFOwG0> NWHqSGhMQTZiaB?= M2DhN4Rm[3KnYYPld{B1cGViY3XscEB3cWGkaXzpeJkhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> MWOyOVM4OzVyOB?=
RKO MlzWR4VtdCCYaXHibYxqfHliQYPzZZk> Mn21NE0yOCEQvF2= NWXhXZF3OjUkgJnoxsA> MXXEUXNQ NYDYdWFzUUN3ME9ihKkzPeLCidM1US=> NF;VN2kzPTNyNEO4Ny=>
Caco-2 NXjnVHFzS2WubDDWbYFjcWyrdImgRZN{[Xl? MYmwMVExKM7:TR?= NVLaO3NLOjUkgJnoxsA> Ml3ZSG1UVw>? NV:1RplNUUN3ME2xPU446oDLwsXN NEDZ[lEzPTNyNEO4Ny=>
DLD1 MnnOR4VtdCCYaXHibYxqfHliQYPzZZk> M3Kw[lAuOTBizszN NW\yZmNIOjUkgJnoxsA> M4L1WGROW09? MYLJR|UxRTF6Lke45qCKyrWP NITtVlMzPTNyNEO4Ny=>
LS411N MoraR4VtdCCYaXHibYxqfHliQYPzZZk> NHXxdJgxNTFyIN88US=> M3vLOFI16oDLaNMg Ml\NSG1UVw>? NXG1fmFTUUN3ME2xNU41P+LCidM1US=> MljVNlU{ODR|OEO=
SW620 MY\D[YxtKF[rYXLpcIl1gSCDc4PhfS=> MoPyNE0yOCEQvF2= M1fHe|I16oDLaNMg Mo\pSG1UVw>? MV\JR|UxRTF{LkK05qCKyrWP Ml7PNlU{ODR|OEO=
HCT116 MVHD[YxtKF[rYXLpcIl1gSCDc4PhfS=> MXywMVExKM7:TR?= MW[yOQKBkWkEoB?= MlPvSG1UVw>? NIHZc3VKSzVyPUKwMlQ66oDLwsXN M2TTdVI2OzB2M{iz
HaCaT MnLWR4VtdCCYaXHibYxqfHliQYPzZZk> NU\LRldIOC5zL{GvNVAh|ryP MVqyOEBp M4\QXmROW09? NXrkRmc1\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy MVmyOVIyODd7NR?=
A5-RT3 MVPD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NVKzcHJiOC5zL{GvNVAh|ryP NHnZUWczPCCq M3jrXGROW09? M1TQdoRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= M1voclI2OjFyN{m1
HaCaT NEDV[HRHfW6ldHnvckBCe3OjeR?= M4fielEx6oDLzszN NXXwPGJyOjRxNEigbC=> MnXaSG1UVw>? MlG0bY5lfWOnczDNUXAh[W6mIFTORUBnemGpbXXueIF1cW:w MWqyOVIyODd7NR?=
A5-RT3 M{W5cmZ2dmO2aX;uJGF{e2G7 NUPmPHVrOTEkgJpOwG0> NXjIZnAyOjRxNEigbC=> MV;EUXNQ NYjXZlJ4cW6mdXPld{BOVVBiYX7kJGRPSSCocnHncYVvfGG2aX;u M17Kd|I2OjFyN{m1
A5-RT3 Mn[5SpVv[3Srb36gRZN{[Xl? M3K1UlUh|ryP M37pSFYhcA>? MVrEUXNQ M3\ZPIlv\HWlZYOgeIhmKHKnbHXhd4Uhd2ZibXn0c4Npd26mcnnhcEBxem:2ZXnud{BidmRicnXkeYNmeyClbH;uc4dmdmmlIIP1dpZqfmGuIHnuJIEh[2G|cHHz[U1qdmSncHXu[IVvfCCvYX7u[ZI> NH7lR4czPTJzMEe5OS=>
U266 MUDGeY5kfGmxbjDBd5NigQ>? NWLQZo5rPTByL{e1NEBvVQ>? MnnBNlQwPDhiaB?= NHnoTYhFVVOR M1X2doRwf26{ZXf1cIF1\XNiQnntMEBxemmwY3nwZYxtgSC2aHWgSWwhcXOxZn;ycS=> MUSyOVIxQDh6OB?=
RPMI8226 Moq1SpVv[3Srb36gRZN{[Xl? MV:1NFAwPzVyIH7N NXPDPHdJOjRxNEigbC=> MWDEUXNQ NFfifmtld3ewcnXneYxifGW|IFLpcUwheHKrbnPpdIFtdHlidHjlJGVNKGm|b3\vdo0> MnPzNlUzODh6OEi=
MM.1S NGDZc2FHfW6ldHnvckBCe3OjeR?= NVi0[ZJNPTByL{e1NEBvVQ>? MnvhNlQwPDhiaB?= MlTQSG1UVw>? NGLkbG9ld3ewcnXneYxifGW|IFLpcUwheHKrbnPpdIFtdHlidHjlJGVNKGm|b3\vdo0> NWHkT3VZOjV{MEi4PFg>
Clone A Mn7oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYOwMlLjiJN4MDFOwG0> MoS1O|IhcA>? M4qwNWROW09? MlHHTWM2OD15LkWg{txO NVXxW|B[OjV{MEi4PFI>
CX-1 NGDQSFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX[wMlLjiJN4MDFOwG0> NIDYU3M4OiCq MlXWSG1UVw>? M{fo[WlEPTB;MT64JO69VQ>? NF\DXVQzPTJyOEi4Ni=>
LS174T NGH3WJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVvpNIIyOC5{4pETOlAh|ryP MWO3NkBp MlPPSG1UVw>? M3LMcmlEPTB;MUiuN{DPxE1? NX7WSFhKOjV{MEi4PFI>
HT29 MUnBdI9xfG:|aYOgRZN{[Xl? M3nSN|EwPS9zMDFOwG0> M3\EeFQ5KGh? M2DFe4NifXOnczDj[YxtKGSnYYToJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy NGHrPYYzPTF7MkG4PC=>
SW480 NH;sb2pCeG:ydH;zbZMhSXO|YYm= MX6xM|UwOTBizszN Mne4OFghcA>? NHHnXolk[XW|ZYOgZ4VtdCCmZXH0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> MXyyOVE6OjF6OB?=
Colo205 NWTyToh4SXCxcITvd4l{KEG|c3H5 MnToNU82NzFyIN88US=> M3z3RlQ5KGh? MlXjZ4F2e2W|IHPlcIwh\GWjdHigbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= MUOyOVE6OjF6OB?=
Caco2 MXHBdI9xfG:|aYOgRZN{[Xl? M4jwfFEwPS9zMDFOwG0> NVTs[4I{PDhiaB?= NVzDPWVi[2G3c3XzJINmdGxiZHXheIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> NIXSPYQzPTF7MkG4PC=>
PCI-13 NESyUlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{nLbVczKGh? NETzZXNFVVOR M13ObWdKPTB;MUWgxtEhOS56IN88US=> NETwSoIzPTF|OUO4Oy=>
PCI-15B NIO0cJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVK3NkBp NWP6XJZ2TE2VTx?= NUmx[GxIT0l3ME2xNUDDuSB2LkWg{txO MkHDNlUyOzl|OEe=
UM-SCC22B NEnmXoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NY\0WpFlPzJiaB?= NFLvd4NFVVOR MWXHTVUxRTF7INMxJFIvQSEQvF2= NIP5V5YzPTF|OUO4Oy=>
UM-SCC47 NETLNJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUe3NkBp M1Tv[mROW09? MXHHTVUxRTF7INMxJFEzNjNizszN NXPsW2dZOjVzM{mzPFc>
93-VU-147T M33RfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHHkdVY4OiCq MmDKSG1UVw>? NXLGfFI3T0l3ME20MlMhyrFiMz61JO69VQ>? M1fwRlI2OTN7M{i3
UD-SCC2 NVy2PWM2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWrkU5Z5PzJiaB?= MkXYSG1UVw>? M4nq[GdKPTB;MkigxtEhOi57IN88US=> MoS5NlUyOzl|OEe=
UPCI:SCC90 Mm\FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGPtT5E4OiCq NXzFO3M2TE2VTx?= M1K0[mdKPTB;Nj62JOKyKDFwNTFOwG0> M3LaSFI2OTN7M{i3
RPMI-8226  NYL4eIR3S2WubDDWbYFjcWyrdImgRZN{[Xl? NVfIWGJROTJ3L{K1NE82ODBibl2= MlHuOFhpyqB? NU\YVnJLTE2VTx?= M2PKfoRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= NVy0TmNoOjVyMEiyNFI>
OPM-2  NHLDeo1E\WyuIG\pZYJqdGm2eTDBd5NigQ>? NVG1WJIxOTJ3L{K1NE82ODBibl2= NX:3Oox4PDiqwrC= M3;XcWROW09? NIf3Unll\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= Mkm0NlUxODh{MEK=
RPMI-8226  M{XOSWFxd3C2b4Ppd{BCe3OjeR?= MnXXNVI2NzJ3MD:1NFAhdk1? Mk\lOFhpyqB? MWDEUXNQ MmfMbY5lfWOnczDj[YxtKGGyb4D0c5NqeyCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? NWj1bYdROjVyMEiyNFI>
OPM-2  M3O3Z2Fxd3C2b4Ppd{BCe3OjeR?= MUWxNlUwOjVyL{WwNEBvVQ>? MlK3OFhpyqB? M{HzcWROW09? M1jvbIlv\HWlZYOgZ4VtdCCjcH;weI9{cXNiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? M3;sdlI2ODB6MkCy
COG-LL-319 NH3xWIRHfW6ldHnvckBCe3OjeR?= MV2xNFAhdk1? NHzNfFYyNzNxNjDo NHqyOHNFVVOR NI[3XldqdmS3Y3XzJINie3Cjc3Wt[IVx\W6mZX70JG1kdC1zIHPs[YF3[Wen NUTlVHdKOjR7NUG0O|I>
RS4;11 NIC5XohHfW6ldHnvckBCe3OjeR?= MYCxNFAhdk1? MUixM|MwPiCq NXPFeocxTE2VTx?= Mn;hbY5lfWOnczDjZZNx[XOnLXTldIVv\GWwdDDNZ4wuOSClbHXheoFo\Q>? M3fVSVI1QTVzNEey

... Click to View More Cell Line Experimental Data

In vivo In aggressive leukemia model, ABT-737 suppresses the leukemia burden by 53% at the 30 mg/kg, with significantly extended survival of mice. ABT-737 does not induce significantly abnormalities in blood cell counts or serum chemistries. [1] ABT-737 prolongs the survival of recipient mice transplanted with Bcl-2-transduced tumors. [2] ABT-737 shows great antitumor activity in an ATLL mouse model at a dose of 100 mg/kg. [5]

Protocol

Kinase Assay:

[1]

+ Expand

Fluorescence polarization assays:

Binding affinity of GST-Bcl-2 family proteins to the FITC-conjugated BH3 domain of Bim (FITC-Ahx-DMRPEIWIAQELRRIGDEFNAYYAR) is determined. Briefly, 100 nM of GST-Bcl-2 family fusion proteins are incubated with serial dilutions of ABT-737 in PBS for 2 min. Then, 20 nM of FITC-Bim BH3 peptide (FITC-Ahx-DMRPEIWIAQELRRIGDEFNAYYAR) is added. Fluorescence polarization is measured using an Analyst TM AD Assay Detection System after 10 min using the 96-well black plate. Then IC50 are determined.
Cell Research:

[4]

+ Expand
  • Cell lines: SCLC cell lines NCI-H889, NCI-H1963, NCI-H1417, NCI-H146, NCI-187, DMS79, NCI-1048, NCI-H82, NCI-H196, H69AR, and DMS114
  • Concentrations: 0.001-10 μM
  • Incubation Time: 48 hours
  • Method:

    SCLC cells are treated for 48 hours in 96-well tissue culture plates in a total volume of 100 μL tissue culture medium supplemented with 10% human serum. Viable cells are determined using the MTS assay.


    (Only for Reference)
Animal Research:

[1]

+ Expand
  • Animal Models: Scid mice injected with Luc-expressing FD/ΔRaf-1:ER cells
  • Formulation: 1 g/mL stock solution of ABT-737 in DMSO is added to a mixture of 30% propylene glycol, 5% Tween 80, 65% D5W (5% dextrose in water) (pH 4−5; final concentration of DMSO ≤ 1%)
  • Dosages: 20 and 30 mg/kg
  • Administration: For intraperitoneal (i.p.) every day
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 100 mg/mL (122.93 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order:
30% Propylene glycol, 5% Tween 80, 65% D5W
For best results, use promptly after mixing.
30mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 813.43
Formula

C42H45ClN6O5S2

CAS No. 852808-04-9
Storage powder
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    What’s the recommended method about reconstitution of the compound for in vivo animal study?

  • Answer:

    For oral administration, we suggest the vehicle: 30% Propylene glycol, 5% Tween 80, 65% D5W, at up to 30mg/ml; For injection, ABT-737 can be dissolved in 2% DMSO/50% PEG 300/5% Tween 80/ddH2O at 2.5 mg/ml.

Bcl-2 Signaling Pathway Map

Bcl-2 Inhibitors with Unique Features

Related Bcl-2 Products

Tags: buy ABT-737 | ABT-737 supplier | purchase ABT-737 | ABT-737 cost | ABT-737 manufacturer | order ABT-737 | ABT-737 distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID